L-Carnitine (Injectable)
Levocarnitine · Carnitine
Amino-acid-derived compound involved in fatty-acid transport; injectable form used in "Lipo" mixes.
Key takeaways
- Approved drug (levocarnitine) for carnitine deficiency; off-label injectable use is the wellness market.
- Meta-analyses show modest weight-loss effects, roughly 1.3 kg over placebo.
- Estimated half-life about 14 hours injected; oral bioavailability is poor, under 20%.
- High doses can cause fishy body odor and GI upset; long-term TMAO concerns are debated.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Carnitine deficiency (label) | 50–100 mg/kg/day (max 3 g/day oral) | Oral or IV | Divided 2–3× daily | Chronic |
| Fat loss / performance (community) | 200–500 mg | IM or SubQ | Once daily | 4–12 weeks reported |
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 14.4 hours
- Bioavailability
- 70%
- Typical dose
- 50–500 mg
Frequently asked questions
Does injectable L-carnitine burn fat?
Not meaningfully in people with normal carnitine status. Meta-analyses of randomized trials find about 1.3 kg extra weight loss versus placebo, and performance benefits are inconsistent. Injections raise blood levels far more than oral, but that hasn't translated into strong outcomes.
Why inject instead of taking capsules?
Oral carnitine absorbs poorly, under 20% bioavailability, so injection raises plasma levels much more. Whether that matters clinically is another question; most positive trial results come from deficient or older populations.
Is L-carnitine safe long-term?
At label doses for deficiency, yes; GI upset and fishy body odor are the common complaints. Gut bacteria convert carnitine to TMAO, which observational studies link to cardiovascular risk, but whether supplemental doses meaningfully raise that risk is unresolved.
References
- Estimated — Quaternary ammonium compound; IV half-life ~hours.
- Obes Rev 2016 — (L-)carnitine and weight loss: systematic review and meta-analysis — Meta-analysis of randomized trials: roughly 1.3 kg additional weight loss versus placebo.
- DailyMed — Levocarnitine injection (label) — Approved indication and dosing for carnitine deficiency.
Related compounds
Semaglutide Injection (Ozempic/Wegovy)
Long-acting GLP-1 receptor agonist for type 2 diabetes and weight loss; weekly injection.
Semaglutide Oral (Rybelsus)
Oral semaglutide with very low bioavailability; taken fasting.
Tirzepatide (Mounjaro)
Dual GIP/GLP-1 agonist for weight loss and diabetes; weekly injection, strong efficacy.
Comments
Loading comments…